伏美替尼治疗奥希替尼耐药非小细胞肺癌16例

Efficacy and safety of furmonertinib in osimertinib-resistant patients with advanced non-small cell lung cancer:16 cases

目的:评价伏美替尼治疗奥希替尼耐药表皮生长因子受体(EGFR)突变的晚期非小细胞肺癌患者的疗效和安全性。方法:选取2021年4月至2023年2月在北京协和医院呼吸与危重症医学科奥希替尼耐药后接受双倍剂量伏美替尼治疗的晚期非小细胞肺癌患者作为研究对象,回顾性分析患者的临床基线特征、基因突变情况、既往治疗情况及伏美替尼的疗效和不良反应。结果:16例患者中男性3例,女性13例,中位年龄62.5岁。患者接受伏美替尼160 mg(qd)治疗,服用至疾病进展或出现不可耐受的不良反应。客观缓解率为0%,疾病控制率为75.0%,中位无进展生存期为4.0个月,不良反应发生率为62.5%,主要为1~2级的胃肠道和皮肤不良反应,未出现因不良反应停药情况。结论:双倍剂量(160 mg,qd)伏美替尼在奥希替尼耐药的患者中可能有较高疾病控制率,且安全性可控。

Objective:To evaluate the efficacy and safety of furmonertinib in treating osimertinib-resistant patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor(EGFR) mutations.Methods:A retrospective analysis of clinical data was conducted in osimertinib-resistant patients with NSCLC,who were administered furmonertinib 160 mg daily from April 2021 to February 2023.The efficacy and safety were evaluated accordingly.Results:A total of 16 patients(13 females;median age 62.5) were enrolled in this analysis.The patients stopped the treatment until the occurrence of disease process or intolerant adverse reactions.Objective response rate was 0%,disease control rate was 75%,and median progression-free survival was 4 months.Treatment-related adverse events occurred in 10 patients(62.5%),including grades 1~2 diarrhea and dermatologic toxicities.No patient discontinued furmonertinib due to adverse events.Conclusion:High-dose furmonertinib 160 mg daily had high disease control rate in osimertinib-resistant NSCLC patients,and toxicity is manageable.